• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583).
  
• Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=17363583).
  

PubMed=3756862
Kevin Maynard, Peter G. Parsons;
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Cancer Res. 46:5009-5013(1986)

PubMed=9354451
Marina Castellano, Pamela M. Pollock, Marilyn K. Walters, Louise E. Sparrow, Louise M. Down, Brian G. Gabrielli, Peter G. Parsons, Nicholas K. Hayward;
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=10070891; DOI=10.1038/sj.bjc.6690147; PMCID=PMC2362648
Shuraila Francisca Zerp, Andrea van Elsas, Lucy T.C. Peltenburg, Peter I. Schrier;
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Br. J. Cancer 79:921-926(1999)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Mitchell S. Stark, Nicholas K. Hayward;
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)